WCM
SCLN

Wedge Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Wedge Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-21,125
Closed -$105K – 523
2013
Q2 		$105K Buy
+21,125
New +$101K ﹤0.01% 484

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Wedge Capital Management's SCLN Position: Q3 2013 in Review

Wedge Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2013, closing a stake of 21,125 shares — an estimated $105K sold.

Wedge Capital Management first reported a position in SCLN in Q2 2013 and held it in 1 quarter. The position peaked at $105K in Q2 2013. 102 funds tracked by Wall St. Rank hold SCLN as of Q3 2013.

  • Wedge Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2013 after selling out during the quarter.
  • Wedge Capital Management sold 21,125 Sciclone Pharmaceuticals Inc shares in Q3 2013, an estimated $105K.
  • Wedge Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 1 quarter.
  • Wedge Capital Management's Sciclone Pharmaceuticals Inc position peaked at $105K in Q2 2013.
  • 102 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2013.

Based on Wedge Capital Management's 13F filing for Q3 2013, filed 23 Oct 2013.